SunTrust Robinson Humphrey Cuts Price target on Pier 1 Imports (PIR) Following 3c EPS Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/14/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Goldman Sachs tech conference highlights AI spending outlook
- Dell shares surge on record AI server bookings
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- 'No panic anywhere' may be the problem, BofA strategists warn
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Pre-Open Stock Movers 09/25: (BLPH) (SIEN) (NKE) Higher; (INAP) (FINL) (PIR) Lower (more...)
September 25, 2015 9:29 AM EDT
Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) 50% HIGHER; announced positive data from an interim analysis of the Company's Phase 2 long-term extension study of INOpulse for the treatment of Pulmonary Arterial Hypertension (PAH) (Part 2 of the Company's Phase 2 trial). The data reinforce the results from Part 1 of the Phase 2 trial and indicate a sustainability of benefit to PAH patients who received INOpulse therapy. Bellerophon also reported today that the U.S. Food and Drug Administration (FDA) has issued a Special Protocol Assessment (SPA) for the Company's... More
After Hours Stocks Movers 09/24: (BLPH) (NKE) (MRVL) Higher; (INAP) (PIR) (BBBY) (more...)
September 24, 2015 5:53 PM EDTBellerophon Therapeutics, Inc. (Nasdaq: BLPH) 61% HIGHER; announced positive data from an interim analysis of the Company's Phase 2 long-term extension study of INOpulse for the treatment of Pulmonary Arterial Hypertension (PAH) (Part 2 of the Company's Phase 2 trial). The data reinforce the results from Part 1 of the Phase 2 trial and indicate a sustainability of benefit to PAH patients who received INOpulse therapy. Bellerophon also reported today that the U.S. Food and Drug Administration (FDA) has issued a Special Protocol Assessment (SPA) for the Company's Phase 3 PAH program for... More
Pier 1 Imports (PIR) Declares $0.07 Quarterly Dividend; 3.2% Yield
September 24, 2015 4:24 PM EDTPier 1 Imports (NYSE: PIR) declared a quarterly dividend of $0.07 per share, or $0.28 annualized.
The dividend will be payable on November 4, 2015, to stockholders of record on October 21, 2015, with an ex-dividend date of October 19, 2015.
The annual yield on the dividend is 3.2 percent.
For... More
Pier 1 Imports (PIR) Misses Q2 EPS by 3c; Guides Q3, FY16 EPS Below Consensus
September 24, 2015 4:07 PM EDTPier 1 Imports (NYSE: PIR) reported Q2 EPS of $0.04, $0.03 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $430 million versus the consensus estimate of $435.38 million.
Company comparable sales increased 2.5% (3.8% on a constant currency basis).
Pier 1 Imports sees FY2015 EPS of... More
Trading Radar for 9/24: Nike (NKE), KB Home (KBH), Bed Bath & Beyond (BBBY), Scholastic (SCHL) Report
September 23, 2015 2:20 PM EDTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:30am EDT
Earnings:
KB Home (NYSE:... More
